Your browser doesn't support javascript.
loading
Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment.
Ades, A E; Gordon, Fabiana; Scott, Karen; Collins, Intira Jeannie; Thorne, Claire; Pembrey, Lucy; Chappell, Elizabeth; Mariné-Barjoan, Eugènia; Butler, Karina; Indolfi, Giuseppe; Gibb, Diana M; Judd, Ali.
Afiliação
  • Ades AE; Population Health Sciences, University of Bristol Medical School, Bristol, United Kingdom.
  • Gordon F; Population Health Sciences, University of Bristol Medical School, Bristol, United Kingdom.
  • Scott K; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Collins IJ; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Thorne C; Population, Policy and Practice Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Pembrey L; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Chappell E; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Mariné-Barjoan E; Public Health Department, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France.
  • Butler K; Children's Health Ireland at Crumlin and Temple Street, Dublin, Ireland.
  • Indolfi G; Meyer Children's Hospital and Department Neurofarba, University of Florence, Firenze, Italy.
  • Gibb DM; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Judd A; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
Clin Infect Dis ; 76(5): 913-991, 2023 03 04.
Article em En | MEDLINE | ID: mdl-35396848
ABSTRACT

BACKGROUND:

Current guidelines recommend that infants born to women with hepatitis C virus (HCV) viremia be screened for HCV antibody at age 18 months and, if positive, referred for RNA testing at 3 years to confirm chronic infection. This policy is based, in part, on analyses that suggest that 25%-40% of vertically acquired HCV infections clear spontaneously within 4-5 years.

METHODS:

Data on 179 infants with HCV RNA and/or anti-HCV evidence of vertically acquired infection in 3 prospective European cohorts were investigated. Ages at clearance of infection were estimated taking account of interval censoring and delayed entry. We also investigated clearance in initially HCV RNA-negative infants in whom RNA was not detectable until after 6 weeks.

RESULTS:

Clearance rates were initially high then declined slowly. Apparently, many infections clear before they can be confirmed. An estimated 65.9% (95% credible interval [CrI], 50.1-81.6) of confirmed infections cleared by 5 years, at a median 12.4 (CrI, 7.1-18.9) months. If treatment were to begin at age 6 months, 18 months, or 3 years, at least 59.0% (CrI, 42.0-76.9), 39.7% (CrI, 17.9-65.9), and 20.9% (CrI, 4.6-44.8) of those treated would clear without treatment. In 7 (6.6%) confirmed infections, RNA was not detectable until after 6 weeks and not until after 6 months in 2 (1.9%). However, all such cases subsequently cleared.

CONCLUSIONS:

Most confirmed infection cleared by age 3 years. Treatment before age 3, if it was available, would avoid loss to follow-up but would result in substantial overtreatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Viral / Hepatite C Tipo de estudo: Guideline Limite: Child, preschool / Female / Humans / Infant Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Viral / Hepatite C Tipo de estudo: Guideline Limite: Child, preschool / Female / Humans / Infant Idioma: En Ano de publicação: 2023 Tipo de documento: Article